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Abstract
Orthologous Cys-loop glutamate-gated chloride channels (GluClR’s) have been cloned and described electrophysiologically
and pharmacologically in arthropods and nematodes (both members of the invertebrate ecdysozoan superphylum).
Recently, GluClR’s from Aplysia californica (a mollusc from the lophotrochozoan superphylum) have been cloned and
similarly studied. In spite of sharing a common function, the ecdysozoan and lophotrochozoan receptors have been shown
by phylogenetic analyses to have evolved independently. The recent crystallization of the GluClR from C. elegans revealed
the binding pocket of the nematode receptor. An alignment of the protein sequences of the nematode and molluscan
GluClRs showed that the Aplysia receptor does not contain all of the residues defining the binding mode of the ecdysozoan
receptor. That the two receptors have slightly different binding modes is not surprising since earlier electrophysiological
and pharmacological experiments had suggested that they were differentially responsive to certain agonists. Knowledge of
the structure of the C. elegans GluClR has permitted us to generate a homology model of the binding pocket of the Aplysia
receptor. We have analyzed the differences between the two binding modes and evaluated the relative significance of their
non-common residues. We have compared the GluClRs electrophysiologically and pharmacologically and we have used site-
directed mutagenesis on both receptor types to test predictions made from the model. Finally, we propose an explanation
derived from the model for why the nematode receptors are gated only by glutamate, whereas the molluscan receptors can
also be activated by b-alanine, GABA and taurine. Like the Aplysia receptor, the vertebrate glycine and GABAA-r receptors
also respond to these other agonists. An alignment of the sequences of the molluscan and vertebrate receptors shows that
the reasons we have given for the ability of the other agonists to activate the Aplysia receptor also explain the agonist
profile seen in the glycine and GABAA-r receptors.
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Introduction
Rapid synaptic transmission in the nervous system is mediated
by a very large and diverse family of ligand-gated ion channels
(LGICs). There are three major divisions in the family based on
channel structure: trimeric, tetrameric and pentameric. Two types
of trimeric LGIC have been described, both of which are cationic
channels: the P2X ATP-activated channel [1] and the proton-
activated acid-sensing ion channels (ASIC) [2].
The major excitatory LGICs in the central nervous system are
glutamate-gated cationic channels [3] that account for all
tetrameric LGICs. One subtype of glutamate receptors - the
NMDA receptors - can only be activated in the presence of a co-
agonist (glycine, serine or alanine [3]) which binds to an
independent site.
The other major group of LGICs are of pentameric structure,
and, in eukaryotes, are characterized by a highly conserved
cysteine loop that is found in the extracellular N-terminal domain.
[4–7]. This characteristic has led to their being labeled ‘‘cys-loop
receptors’’. The pentameric receptors, unlike those of the trimeric
and tetrameric groups, include receptors for many different
neurotransmitters: ACh [8], GABA [9], glycine [10], serotonin
[11], glutamate [12–15], histamine [16–17] dopamine and
tyramine [18], and other LGICs that are inhibited [19] or gated
by protons [20–21], or gated by Zn2+ [22]. Furthermore, a given
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transmitter type can be associated with both a cationic and an
anionic channel (e.g., ACh [23], GABA [9,24], 5-HT [11,25]).
Most of this diversity is found in invertebrates [12–27].
The pentameric receptors can, themselves, be further divided
into two distinct groups: those containing only the cys loop which
is associated with all eukaryote pentameric receptors and those
which have been labeled 2-cys-loop receptors [26] since they
contain an additional cys loop in the N-terminal domain.
The 1-cys loop receptors include both excitatory (cationic) and
inhibitory (anionic) receptors whereas all 2-cys loop LGICs
discovered to date are anionic. The glycine receptor [10] is the
best known example of the 2-cys loop receptors, and the only
vertebrate one. In invertebrates, 2-cys-loop receptors have been
found that are activated by either glutamate [12–15] or histamine
[16–17] and others which are inhibited [19] or gated [20] by
protons.
Until recently the only invertebrate 2-cys loop receptors that
had been cloned, expressed, and for which a function had been
determined were from nematodes and arthropods. Those two
phyla represent only one of the two major superphyla of
invertebrates - the ecdysozoa. In 2009 the cloning of glutamate-
gated chloride channels from the mollusc Aplysia californica [14]
provided sequences of 2-cys loop receptors from the other major
group of invertebrates - the lophotrochozoa, consisting principally
of molluscs and annelids.
A phylogenetic analysis was performed [14] on the ecdysozoan
2-cys-loop receptors described above, the mammalian glycine
receptor, the Aplysia glutamate receptors and homologs of the
Aplysia receptors taken from genomes recently sequenced by the
Joint Genome Institute from two other lophotrochozoa: the
mollusc Lottia gigantea and the annelid, Capitella teleta. The
analysis revealed that the glutamate receptors from nematodes and
arthropods (ecdysozoa) are, phylogenetically speaking, indepen-
dent of the glutamate receptors from the molluscs and annelids
(lophotrochozoa). Either the receptors from these two groups share
a common ancestral glutamate-sensitive protein from the deep
roots of the metazoan lineage, or the binding of glutamate to these
two receptor types results from convergent evolution. A similar
phylogenetic independence of nematode and molluscan 1-cys-loop
ACh-gated chloride channels has been noted [26–28].
The conclusion that the Aplysia and nematode glutamate-gated
chloride channels were not orthologs was not a complete surprise.
Electrophysiological studies of glutamate-gated chloride channels
in Aplysia neurons and of heterologously-expressed glutamate
receptor subunits from C. elegans had already suggested the
existence of pharmacological differences in the receptors from the
different phyla. Whereas GABA and b-alanine had been shown to
activate the Aplysia neurons bearing the glutamate receptor [29–
30], no sign of a response to GABA was seen from the
heterologously expressed nematode receptor [31–32], although
the GABA concentrations used were relatively low given the high
EC50’s for glutamate that were recorded for those receptors.
In 2011 the crystalization by Hibbs and Gouaux [33] of one of
the alpha subunits of the 2-cys-loop glutamate receptor from C.
elegans defined the binding mode of that receptor. An alignment
of the protein sequence of the nematode glutamate receptor with
that from the Aplysia reveals that the Aplysia receptor does not
contain, in homologous positions, all of the residues belonging to
the binding pocket of the nematode receptor.
Knowing the structure of the binding pocket of the ecdysozoan
receptor has made it possible for us to predict, by homology
modeling, the binding mode of one of the two glutamate-gated
chloride channels in Aplysia and to confirm, by site-directed
mutagenesis, predictions drawn from the model. Heterologous
expression of both the C. elegans and Aplysia receptors in the same
expression system has made it possible to establish certain
distinctive pharmacological characteristics of the two receptor
types and to suggest, in light of the model, a possible reason for
these differences.
Methods
Cell culture, mutagenesis and electrophysiology
Cell culture and transfection. Chinese Hamster Ovary
(CHO-K1) cells were obtained from the American Type Tissue
Culture Collection (ATCC, Molsheim, France) and maintained
in HAM-F12 nutrient mix+GluaMAX supplement (Life Tech-
nologies) after adding 10% fetal bovine serum (Gibco 10500)
and 1% PenStrep (Gibco 15140). Cells were plated in 35 mm
Falcon easy grip dishes and were split one to three days prior to
transfection directly into new 35 mm dishes with 2 ml of
medium. On the day of, but prior to, transfection the old
medium was replaced by 1 ml of fresh medium. cDNAs were
introduced into the CHO cells using the transfection agent
Exgen 500. The protocol prescribed by Thermo Scientific was
adapted for use with 35 mm dishes and for the amount of
cDNA used in each transfection. 1 mg of a WT or mutated
glutamate receptor cDNA (see above) was co-transfected with
1 mg of Green Fluorescent Protein (GFP). Our procedures,
however, included one exception to the Exgen protocol: the
transfection dish contained only 1 ml of medium for the first
80 min of exposure to the DNA-Exgen mix. At the end of that
time period, one more ml of medium was added and the
Exgen-cDNA containing milieu was left in the dish, as suggested
by the Exgen protocol. The fluorescent cells were studied,
electrophysiologically, 24–30 hours after the initiation of
transfection.
Fast perfusion system and electrophysiological
recording. A modified perfusion system from ALA Scientific
Instruments, with an 8-channel solenoid valve manifold (VC-3-8),
was used for applying a constant rapid flow of solution directly
onto the cell under study. At most six syringe and tube assemblies
(PE-20) containing various agonists and/or various agonist
concentrations fed into a Warner Instruments ML-6 miniature
manifold from which the control external solution or agonist-
containing solution exited through a BD Microlance hypodermic
needle (25 g, 25 mm, 10 regular wall) approximately 30–50 mM
from the cell. All solutions were gravity fed from these syringes
which were approximately <50 cm above the preparation. An
agonist was typically applied for 1 sec followed by a 3-min flow of
control solution through the same tube (see above). In addition,
the dish of transfected cells was continuously superfused with
external control solution through an independent tube.
Whole-cell recordings were conducted at room temperature
(20–25uC) using an EPC-9 amplifier (HEKA Elektronik, Ger-
many). The external solution contained (in mM): NaCl 140, KCl
5, CaCl2 2, MgCl2 1, HEPES 20, and glucose 25 brought to
pH 7.4 with NaOH; <310–320 mOsm. The patch pipette
solution contained (in mM): KCl 140, MgCl2 2, MgATP 2,
NaGTP 0.4, HEPES/KOH 10, BAPTA/KOH 20; pH 7.3;
<290 mOsm. Pipettes were pulled from borosilicate glass
capillaries (with filament) on a vertical pipette puller (L/M-3P-A,
List-Medical, Darmstadt, Germany) and had resistances of 3–6
MOhms. Only cells with an input resistance over 300 MOhms
were used in the experiments reported here.
The choice of glutamate-gated chloride channels from C.
elegans and Aplysia californica. For the electrophysiological
and pharmacological evaluation of the glutamate-gated chloride
Molecular Determinants of Agonist Binding in GluClRs
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channel from C. elegans we chose not to use the GluCla1 subunit
[12] – a slight modification of which was crystalized by Hibbs and
Gouaux [33]. Neither GluCla1 nor its modified version,
GluClCryst, respond to glutamate without a preactivation by
ivermectin [12,33] due to a failure of that subunit to couple agonist
binding to channel gating [31]. Consequently, we have chosen
another alpha subunit from C. elegans - GluCla2b [32] (accession
number CAA04170) - which does respond directly to glutamate.
GluCla2b, like the other alpha subunits of the glutamate-gated
chloride channels of nematodes and arthropods, has the same
binding residues as does the crystalized receptor. The glutamate-
gated chloride channel from Aplysia that was used for both the
homology model and the electrophysiological and pharmacolog-
ical comparison was GluClAc2 [14] (accession number
NP_001191520).
Site-directed mutagenesis. The QuickChange site-directed
mutagenesis kit by Stratagene (Agilent Technologies) was used for
mutating specific residues in GluClAc2 and in GluCla2b. In the
event that two or three residues were to be mutated, the mutations
were performed successively: i.e., an additional mutation was
made on an already mutated receptor. All mutations were
confirmed by sequencing.
Homology modeling, molecular dynamics and docking
Homology modeling. All calculations were performed in
Discovery Studio 3.5 (Accelrys Software Inc., San Diego, CA).
Homology model for glutamate-binding domain of
GluClAc1 and GluClAc2. The sequence and crystallographic
structure of the glutamate-binding domain of the C. elegans
GluClCryst receptor were retrieved from the PDB (PDB code:
3RIF). The GluCl receptors, like the glycine receptor, are
pentamers. Glutamate binds between two subunits of this
pentamer. Hence, to accurately analyze glutamate binding in C.
elegans and Aplysia, the sequence, structure and models of two
subunits were always considered.
The sequence of the glutamate-binding domain of Aplysia
GluClAc1 and GluClAc2 receptors were retrieved from the NCBI
database (NCBI codes: NP_001191519 and NP_001191520
respectively). The sequences of GluCla1, GluClAc2 and GluClCryst
were aligned using the Align123 algorithm [34], and the resulting
sequence alignment was then further used for comparative
modeling.
Models of GluClAc1 and GluClAc2 (two adjacent subunits of
each of the two receptors) were generated using MODELER [35].
For each receptor, 100 models were generated but only the ten
best with respect to lowest PDF Energy (as provided by
MODELER) were considered for further analysis.
Subsequently we calculated their Profiles_3D scores [36–37]
and the percentage of amino-acids in disallowed regions of the
Ramachandran plot. For each receptor, the model exhibiting the
best consensus between the three properties cited above was
chosen for molecular dynamics.
During all the model building process, the glutamate present in
the template was kept and transferred into the models. As a result,
glutamate was already positioned for subsequent calculations.
Molecular dynamics. Protein-ligand interactions (Glu-
ClAc1-glutamate and GluClAc2-glutamate) were further opti-
mized by 2 ns molecular dynamics using CHARMm [38]. Once
the trajectory was equilibrated, snapshots of the trajectory were
analyzed in terms of protein-ligand contacts and the selected ones
were submitted to a final CHARMm-based energy minimization.
Mutated GluClAc1 receptor. The protein sequence of
GluClAc1 was modified (S95R and K158Y mutations were
introduced) and the above mentioned protocol was performed
on this sequence.
Docking of additional ligands. For each docking experi-
ment, the ligand was initially positioned in the binding site using
CDOCKER. CDOCKER uses a CHARMm-based molecular
dynamics (MD) protocol to dock ligands into a receptor binding
site [39]. Random ligand conformations were generated using
high-temperature MD. The conformations were then translated
into the binding site and candidate poses were then created using
random rigid-body rotations followed by simulated annealing. A
final CHARMm-based energy minimization was then used to
refine the ligand poses.
Results and Discussion
Electrophysiological and pharmacological evaluation of
GluCla2b (C. elegans) and GluClAc2 (Aplysia californica)
Differential desensitization properties of the two
receptors. Under the conditions used here to study the
responses of the two receptors to glutamate, the GluClAc2
receptor was found to desensitize much more rapidly than does
the GluCla2b receptor. The response of the GluClAc2 receptor to
a 1-sec application of 1 mM glutamate reaches a maximum
rapidly and, by the end of the 1-sec application, is already reduced
to 27% of its maximum amplitude, whereas the response of
GluCla2b is only reduced to 63% of its maximum at that time
(One-way ANOVA, p,.0001, n= 10 and SE=0.04 for both
evaluations). This differential desensitization is also seen when
evaluating the constancy of the response amplitude over repeated
applications: a 1-min interval between 1-sec applications of 1 mM
glutamate is insufficient for recovering a constant response
amplitude from the GluClAc2 receptor, whereas an essentially
identical response can be obtained from GluCla2b receptor with
that protocol. Because of this difference a minimum of a 3-min
interstimulus interval was always used when analyzing the
properties of the GluClAc2 receptor (see Methods).
Sensitivity to glutamate of the two receptor types. The
EC50 of the glutamate response of GluClAc2 expressed in CHO
cells has already been estimated to be 196 mM [14]. In contrast,
the only published EC50 for GluCla2b was obtained by expression
in Xenopus oocytes [32] and was found to be 2 mM. To examine
the sensitivity of the two receptor types in the same expression and
perfusion systems we have not attempted to do full concentration-
response curves, but have compared their responses only to
100 mM, 1 mM and 10 mM glutamate. In GluCla2b, the
response to 1 mM was 94% of that to 10 mM (n= 14, SE= 2.1);
in GluClAc2, 95.5% (n= 17, SE= 1.8) (one way ANOVA,
p= 0.6). These results suggest that both receptors have, in our
system, reached saturation at 1 mM.
On the other hand, a difference in the sensitivity of the two
receptors to 100 mM glutamate was observed: in GluCla2b, the
response to 100 mM was only 12.2% of that to 1 mM glutamate
(n = 14, SE= 5); in GluClAc2, 57% (n= 14, S= 5) (one-way
ANOVA, P,0.0001). This difference at lower concentrations
reinforces the estimates of relative sensitivity of the two receptors
drawn from published data obtained from different expression
systems (see above).
Agonist specificity of the two receptor types. The
glutamate-gated chloride channels of Aplysia have been shown,
both in situ [29–30] and in homomeric expression in CHO cells
[14], to be activated by both GABA and b-alanine. Given the high
EC50’s for the response to glutamate of the GluCla2b receptor
expressed in Xenopus oocytes [32], the concentrations used to
evaluate the sensitivity of that receptor subunit to GABA (the only
Molecular Determinants of Agonist Binding in GluClRs
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other agonist tested) could have missed a low sensitivity to that
amino acid. Consequently, we have tested here, under identical
transfection, recording and fast perfusion conditions, the differen-
tial sensitivity of the two receptor types to GABA, b-alanine and
taurine, all of which are known to be present in the mammalian
nervous system and all of which activate the glycine and GABAA-r
receptors [40–44]. A comparison of the responses of GluClAc2
and GluCla2b to glutamate and the other three agonists can be
seen in Fig. 1.
The records labeled ‘‘Ac’’ in column I are typical recordings of
the responses of GluClAc2 to 1 mM glutamate and to 1 and
10 mM of either GABA (A, Ac), b-alanine (B, Ac), or taurine (C,
Ac). All of the latter three agonists elicited responses to both the 1
and 10 mM concentrations.
In contrast, the records labeled ‘‘a2b’’ in column I, which show
the responses obtained from GluCla2b, reveal that, in spite of a
robust response to 1 mM glutamate, no currents could be elicited
by 10 or 50 mM of either GABA (A, a2b), b-alanine (B, a2b), or
taurine (C, a2b).
A similar difference in the two receptor types was seen when we
evaluated the ability of the three other agonists to desensitize or
block the responses of the two receptors to glutamate. In the
records in the right hand column of Fig. 1 (II), during the 3-min
interval separating 1-sec applications of glutamate, one of the three
other agonists (A, B, C) was applied. The records preceded by Ac9
are from the GluClAc2 receptor, and the 3-min application of
1 mM of the non-glutamate agonist (A, Ac9 GABA; B, Ac9 b-
alanine; C, Ac9 taurine) can be seen to have completely eliminated
the response to the second application of glutamate.
In contrast, in cells expressing the GluCla2b receptor (records
preceded by a2b9), the glutamate response that immediately
follows a 3-min application of a 10 times higher concentration
(10 mM) of either GABA, b-alanine or taurine is essentially
identical to that preceding the ‘‘desensitizing’’ agonist (see A, a2b9,
B, a2b9 and C, a2b9, respectively).
These findings confirm the conclusion drawn from the
experiments done in Xenopus oocytes [32], i.e. that, GABA does
not gate the GluCla2b receptor. They also show that the same
conclusion can be drawn concerning b-alanine and taurine.
A comparison of the crystallographic structure of the C.
elegans glutamate-gated chloride channel and the
homology model of GluClAc2 derived therefrom
Analysis of the sequence alignment of GluClCryst and
GluClAc2. The similarities and differences between the nema-
tode and Aplysia receptors are clearly represented in the sequence
alignment shown in Fig. 2 which reveals that out of the seven
binding residues identified in the crystallographic structure of the
nematode receptor (each surrounded by a black rectangle), five are
aligned with identical residues in GluClAc2 (colored in green in
Fig. 2). One of the other binding residues of GluClCryst (see residue
position 201, colored in yellow) is aligned with a residue in
GluClAc2 which could have a similar function (a tyrosine in
GluClCryst can be seen to be aligned with a phenylalanine in
GluClAc2). The remaining binding residue of GluClCryst, in
contrast, aligns with a residue in GluClAc2 that cannot assume a
similar function: the arginine in GluClCryst at position 37 is aligned
with a leucine in the GluclAc2 receptor. These two residues are
clearly functionally different, and they thereby permit us to
envision some differences in the way the receptors are binding
glutamate. The residues at position 37 are colored in red.
Three additional residues surrounded by red rectangles in Fig. 2
will be discussed only after the description of Fig. 3 which presents
the proposed binding pocket of GluClAc2 predicted by the
homology model. Note that none of the aligned residues
surrounded by a red rectangle are identical, none are colored,
and one of each of the three pairs of aligned residues belongs to the
binding pocket of GluClAc2.
Crystallographic structure of GluClCryst and the
homology model of GluClAc2. The homology model of
GluClAc2 (see Materials and Methods) along with the crystallo-
graphic structure of GluClCryst has made it possible to compare the
different amino acids interacting with glutamate in the two
receptors.
Comparison of the binding modes of the two
receptors. The GluClCryst receptor is a pentamer, and Hibbs
and Gouaux [33] have confirmed that glutamate binds between
two adjacent subunits: the Principal (P) and Complementary (C)
subunits as defined by Corringer et al. [45]. The relevant subunits
with which the residues in Fig. 2 are associated have been
indicated in the figure legend, and these subunits are represented
schematically in Fig. 3.
The binding pockets of the GluClCryst and GluClAc2 receptors,
respectively, are represented in Fig. 3A with four of the important
residues cited above shown as sticks associated with the Principal
or Complementary subunit (colored in violet or green/yellow,
respectively) to which each belongs.
As can be seen in Figures 3 and 4, the serine and the tyrosine
that are seen in both receptors at positions 150 and 151,
respectively, bind the a-amino group directly, as do the tyrosine
and phenylalanine residues seen at position 201 in the GluClCryst
and GluClAc2 receptors, respectively. The two aromatic rings of
residues at positions 151 and 201 each make a cation-p interaction
with the a-amino group of the ligand (Figures 3B and 4). Likewise,
the three residues binding the c-carboxyl group of GluClCryst (at
positions 56, 121 and 198) are the same in GluClAc2 (see
Figures 3B and 4).
The homology model of GluClAc2 (Fig. 3B) proposes an
additional H-bond between the c-carboxyl group of glutamate
and residue Y161 (position 119, surrounded in red in Fig. 2) that is
not present in the crystallographic structure of GluClCryst.
However, it will be shown below that Y161 is not an essential
residue in GluClAc2.
The major differences in the two binding pockets reside in the
binding of the two receptors to the a-carboxyl group of the ligand.
As shown in Fig. 3, the residue at position 37 (Fig. 2) that is shown
to bind glutamate in GluClCryst is not predicted to bind glutamate
in GluClAc2 (Fig. 3A and B). Likewise, the residue at position 93
(Fig. 2, surrounded by a red rectangle) aligns with a proline in
GluClCryst that was not found to bind glutamate in that receptor,
whereas the arginine found at that position in GluClAc2 is
predicted to bind to the a-carboxyl group. Although in both
receptors the a-carboxyl group is involved in a salt bridge with an
arginine, these two arginines - R37 in GluClCryst and R135 in
GluClAc2 (positions 37 and 93) - are neither aligned (Fig. 2), nor
do they belong to the same subunit (Figures 3 and 4). Secondly,
there is no equivalent in GluClCryst for Y96 (position 54,
surrounded in red in Fig. 2) which is predicted by the homology
model for GluClAc2 to make a side-chain hydrogen bond with the
a-carboxyl group and a hydrophobic contact with the backbone of
glutamate (Figures 3 and 4).
Examination of GluCla2b in light of the GluClCryst binding
pocket. It should be recalled (see Methods) that the alpha
subunit from which GluClCryst was developed (GluCla1, accession
# AAA50785) does not respond to glutamate without prior
activation by ivermectin [12]. Thus it was not an adequate subunit
for either evaluating the effects of mutations in the nematode
receptor or for testing the sensitivity of that receptor to other
Molecular Determinants of Agonist Binding in GluClRs
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Figure 1. Differential sensitivity of GluClAc2 and GluCla2b receptors to glutamate, GABA, b-alanine and taurine. Column labeled I:
Traces preceded by Ac: Responses of GluClAc2 to a 1-sec application of (A) 1 mM glutamate, 1 mM GABA and 10 mM GABA; (B) 1 mM glutamate,
1 mM b-alanine and 10 mM b-alanine; and (C) to 1 mM glutamate, 1 mM taurine and 10 mM taurine. Traces preceded by a2b: Responses of GluCla2b
Molecular Determinants of Agonist Binding in GluClRs
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agonists. Consequently, we selected another alpha subunit of the
nematode receptor (GluCla2b, accession# CAA04170) which has
the same binding mode as GluClCryst, but which responds directly
to glutamate [32]. While all of the glutamate binding residues are
conserved in the two nematode sequences (not shown), the present
study identifies, at position 93, a critical arginine in GluClAc2 (see
R135 in Figures 3 and 4) that aligns with a proline (P93) in
GluClCryst, but with a glutamine in GluCla2b (Q167; not shown).
Simulations showed that this difference in the residue at position
93 in the two nematode receptors does not change their binding
properties. We have therefore used the structure of GluClCryst to
elucidate the effect of mutations in GluCla2b.
Site-directed-mutagenesis
The Mutations in the GluClAc2 receptor and their effects
on the response to glutamate. The homology model of the
GluClAc2 binding pocket predicts that glutamate binds to five of
the same residues to which it binds in the nematode binding
pocket, as well as to a sixth ‘‘similar’’ residue. The alignment in
Fig. 2 shows that these residues are found at positions 56, 121,
150, 151, 198 (green background in Fig. 4), with the sixth residue
at position 201 (yellow background in Fig. 4). These positions
correspond to residues R56, S121, S150, Y151, T197 and Y200 in
GluClCryst, to residues R130, S195, S224, Y225, T271 and Y274
in GluCla2b; and to residues R98, S163, S192, Y193, T238 and
F241 in GluClAc2. The homology model also predicts that, in
GluClAc2, glutamate binds to three additional residues which are
not included in the binding mode of the nematode receptor: Y96,
R135 and Y161 at positions 54, 93 and 119, respectively (shown in
Fig. 2 surrounded by a red rectangleand in Fig. 4 on a red
background). Mutations were performed on four of the above
residues in the GluClAc2 receptor: Y96, R98, R135 and Y161.
Figure 5A reveals the differential importance of the mutations of
these residues for the response to glutamate in GluClAc2. As was
mentioned above, both of the WT receptors respond to 100 mM
glutamate, and here it can be seen that there is no response in
many of the mutations to a 10 fold higher concentration (i.e.,
1 mM).
Unlike most of the mutations, that of residue Y96 (position 54,
see Fig. 2) to a phenylalanine caused no change in the response to
glutamate (Fig. 5A, Y96F). On the other hand, when that same
residue was mutated to either an alanine or a threonine (the latter
of which is the residue at the same position in the nematode
receptor) the response was completely eliminated. As can be seen
in Fig. 6A, the Y96A and Y96T mutations rendered the receptors
unresponsive even to a 100 mM glutamate concentration.
As can be seen in Fig. 5A, the response to 1 mM glutamate was
also lost when the residue R98 (position 56) was replaced by a
serine (R98S) or when R135 (position 93) was replaced by an
alanine (R135A). However the persistence of the deleterious effect
to a 1-sec application of (A) 1 mM glutamate, 10 mM GABA and 50 mM GABA; (B) 1 mM glutamate, 10 mM b-alanine and 50 mM b-alanine; and (C)
1 mM glutamate, 10 mM taurine and 50 mM taurine. Column labeled II: Traces preceded by Ac9: Responses of GluClAc2 to a 1-sec application of
glutamate before and after a 3-min application of (A) 1 mM GABA; (B) 1 mM b-alanine, and (C) 1 mM taurine. Traces preceded by a2b: Responses of
GluCla2b to a 1-sec application of glutamate before and after a 3-min application of (A) 10 mM GABA; (B) 10 mM b-alanine, and (C) 10 mM taurine.
All applications of glutamate or other agonists were separated by a 3-min interval (during which the control solution bathed the cell), except in
column II where a second agonist (GABA, b-alanine, or taurine) was applied during the 3-min interval separating glutamate applications.
doi:10.1371/journal.pone.0108458.g001
Figure 2. Alignment used for homology model building. Sequence alignment of residues of the two GluCl receptors: the first, a receptor from
C. elegans, GluClCryst, which has been crystalized and which will serve as the template for the homology model of the second, GluClAc2, from the
Aplysia californica. The numbers above the sequence represent the positions in the alignment based on the truncated receptor from GluClCryst. The
last line describes the secondary structure of GluClCryst with the blue arrows representing b-sheets and the orange tubes, the a-helices. Throughout
the length of the sequences, a light blue highlighting indicates identical or similar residues. Residues binding glutamate in GluClCryst are surrounded
by a black rectangle. These positions are highlighted in green, yellow and red when the aligned residue in GluClAc2 is respectively identical, similar or
different. Three additional positions are surrounded by a red rectangle and correspond to positions of residues binding glutamate only in the
homology model of GluClAc2.
doi:10.1371/journal.pone.0108458.g002
Molecular Determinants of Agonist Binding in GluClRs
PLOS ONE | www.plosone.org 6 September 2014 | Volume 9 | Issue 9 | e108458
Figure 3. Glutamate bound to GluClCryst and to the homology model of GluClAc2. A. 3D representation of the binding pocket of glutamate
at the interface between the two subunits of the crystallographic structure of GluClCryst (Left) and the model of GluClAc2 (Right). The Principal and
Complementary subunits are displayed in violet and green/yellow, respectively. The bound glutamate is represented by a ball and stick display. The
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of the two mutations at higher concentrations differed significant-
ly. Whereas, even at 100 mM glutamate, there was no sign of a
response from the R98S mutation, in the receptor with the R135A
mutation a small response was obtained with 10 mM, and a robust
response was obtained with 50 and 100 mM glutamate (Fig. 6A).
The residue Y161 (position 119 see Fig. 2) was found not to be
critical for binding glutamate since its mutation to an alanine failed
to cause any noticeable change in the response to glutamate, as
can be seen in the last record of Fig. 5A.
Modifications of the non-binding residues in one receptor
that are aligned with a binding arginine in the other
residues for four important positions in the alignment are represented as sticks, and their names and residue numbers are written in green. B. 2D
diagram representing the interactions between glutamate and each of the two receptors: GluClCryst (Left) and GluClAc2 (Right) as displayed in 3A.
Glutamate is represented in lines, and adopts two different conformations reflecting the respective bindings at the two receptors. Only the polar
hydrogens that are involved in interactions with the receptor are explicitly represented. Residues are depicted as circles in which the residue type,
number and position (the latter in parentheses) are written on a colored background which indicates the subunit to which the residue belongs (see
Fig. 3A). Backbone and side chain hydrogen bonds are represented by green and blue arrows, respectively. Salt bridges are represented by violet
arrows and p interactions are represented by orange lines. Atom color code: carbon gray, oxygen red, nitrogen blue, hydogens white in A, black in B.
doi:10.1371/journal.pone.0108458.g003
Figure 4. Summary of the interactions of glutamate in GluClCryst and GluClAc2. List of residues (as identified from the crystallographic
structure of GluClCryst and predicted by the GluClAc2 homology model) accompanied by their position number in the alignment of Fig. 2 and a
description of the type of interactions in which they are involved. Residue numbers are given for the crystalized receptor (GluClCryst), the receptor
used in the electrophysiological experiments (GluCla2b), and the receptor that figures in the homology model (GluClAc2) from left to right,
respectively. Rows in green, yellow and red indicate identical, similar and different aligned residues, respectively.
doi:10.1371/journal.pone.0108458.g004
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receptor. We also mutated, in each of the receptors, a non-
binding residue that aligns with a critical binding arginine in its
homolog. Thus, the non-binding leucine L79 in GluClAc2
(position 37, Fig. 2) was mutated to an arginine. This mutation
resulted in adding a supplementary arginine to the binding pocket,
and, as can be seen in Fig. 5B (L79R), this additional arginine
eliminated the response to 1 mM glutamate - as it did at all
concentrations of glutamate (see Fig. 6A).
In GluCla2b, in contrast, the addition of an arginine at position
93 by the Q167R mutation (Fig. 5C) only reduced, but did not
completely eliminate, the response to 1 mM glutamate which
recovered at higher glutamate concentrations (Fig. 6B).
Mutations in both receptors designed to evaluate the
significance of ‘‘non-aligned’’, binding arginine
residues. We also verified the significance of each of the
‘‘non-aligned’’ binding arginine residues. We first mutated the
residue R135 (position 93, see Fig. 2) of GluClAc2 to an alanine.
As can be seen in Fig. 5A, that non-aligned arginine affects
glutamate binding in the Aplysia receptor since the response to
1 mM glutamate was eliminated. However, it is considerably less
effective in inhibiting the response to 10, 50 and 100 mM
glutamate than are the other GluClAc2 mutations (see Fig. 6A).
The corresponding non-aligned, binding arginine found in the
GluCla2b receptor at position 37 was mutated to a leucine (the
amino acid found in the homologous position in GluClAc2). This
arginine mutation affected glutamate binding (see R111L in
Fig. 5C), although a greatly reduced response to 1 mM glutamate
could sometimes be obtained and, as can be seen in Fig. 6B, this
mutation did not impede a robust response to glutamate at higher
concentrations.
Double mutations were made of the residues at positions 37 and
93 in both GluClAc2 and GluCla2b. These mutations introduced
a switch of the positions of their non-common arginines. This was
done in order to evaluate the effect of the position of the second
arginine on the ability of each of the receptors to bind glutamate.
The switched positions in GluClAc2 eliminated the response to
glutamate at all concentrations (see L79R+R135A in Figures 5B
and 6A), whereas in the cells bearing the corresponding double
mutation in GluCla2b receptor (see R111L+Q167R) higher
concentrations of glutamate elicited responses in the 100’s of pA
(Fig. 6B).
Triple mutations in the two receptors. Finally, triple
mutations of the amino acids either binding the a-carboxyl group
or aligned with amino acids in the second receptor that do so bind
were also performed (not shown in Fig. 5). As with the double
mutations, this complete exchange of the three residues in
positions 37, 54 and 93 (see Figures 3B and 4) rendered GluClAc2
unresponsive at all concentrations of glutamate (Fig. 6A), whereas,
once more, the corresponding exchange of residues in GluCla2b
did not impede the appearance of responses in the hundreds of nA
to higher glutamate concentrations.
Summary of the effects of the mutations in both
receptors. Whereas six of the seven mutated GluClAc2
receptors remained essentially unresponsive to all concentrations
of glutamate (highest average response to 100 mM glutamate in
the 6 receptors was 62 pA), four of the five mutated GluCla2b
receptors responded robustly to 10, 50 and 100 mM glutamate. In
both receptors the mutation of the residue at position 93 (Fig. 6)
was the least damaging. In GluClAc2, the receptor bearing that
mutation (R135A) was the only one of the seven mutations that
showed a response to glutamate at higher concentrations, and its
behavior as a function of glutamate concentration (see Fig. 6A)
was found to be significantly different from all of the other
GluClAc2 mutations grouped together for a 2-way ANOVA (p. ,
.0001).
Of the mutations performed on GluCla2b, as in the
corresponding mutation in the Aplysia receptor, that of the
residue at position 93 (Q167R) showed robust responses at
increasing glutamate concentrations. However, unlike in the
Aplysia receptor, responses to 10, 50 and 100 mM could be seen
Figure 5. Responses to 1 mM glutamate in both WT and mutated GluClAc2 and GluCla2b receptors. A. Mutations in four binding
residues of GluClAc2: Y96, R98, R135 and Y161 (positions 54, 56, 93 and 119). B. Mutations in GluClAc2 of residues L79 alone and L79+R135. These two
residues are found at positions 37 and 93 (see Figs. 3 and 4). Only one of the two (R135) belongs to the GluClAc2 binding pocket (see the R135A
mutation alone in A). C. Mutations in GluCla2b of residues R111 and Q167 found at positions 37 and 93, respectively: R111 alone, and R111+Q167 in a
double mutation. Only one of the residues (R111) belongs to the GluCla2b binding pocket. Calibration: A: 1 sec, 500 pA; B: 1 sec, 500 pA; C: 1 sec,
1000 pA.
doi:10.1371/journal.pone.0108458.g005
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for all of the mutations in GluCla2b except for the T128Y
mutation which, like six of the mutations in GluClAc2, remained
essentially unresponsive even to high glutamate concentrations
(Fig. 6B). The responses seen as a function of glutamate
concentration in the five mutated GluCla2b receptors were shown
to differ significantly (2-way ANOVA, P,.0001). Of the five
mutated nematode receptors only the comparison of the R111L+
Q167R and R111L+Q167R+T128Y mutations failed to yield a
significant difference (2-way ANOVA, p= .37).
The effect of the mutations on the response of the two
receptors to GABA. In the two mutated GluClAc2 receptors
for which there was no reduction in the response to glutamate
(Y161A and Y96F at positions 119 and 54, respectively) the
Figure 6. Responses of mutated GluClAc2 and GluCla2b receptors to increasing concentrations of glutamate. A: Responses (in pA) of
seven mutated GluClAc2 receptors to 1, 10, 50 and 100 mM glutamate. B: Responses of five mutated GluCla2B receptors to 1, 10, 50 and 100 mM
glutamate.
doi:10.1371/journal.pone.0108458.g006
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amplitude of the responses to 1 and 10 mM GABA likewise
remained unaffected (not shown).
For the R135A (position 93) mutation there was a shift in
sensitivity to both glutamate and GABA, with the threshold
response for glutamate shifting from 1 to 10 mM, and that of
GABA from 10 to 50 mM. For all of the other mutations in
GluClAc2 there was a total disappearance of the response to
GABA as there was for the response to glutamate. None of the
mutations in the GluCla2b receptor transformed it into a GABA-
sensitive receptor – even when tested with a 100 mM concentra-
tion of the agonist.
Justification, in light of the model, for the effects of the
mutations
Y161 is not essential for the binding of glutamate in
GluClAc2. As was mentioned above, mutating Y161 (position
119) to an alanine did not affect the activity of the receptor
(Fig. 5A). Indeed, in GluClAc2 as in GluClCryst, the c-carboxyl
group of glutamate is also interacting with an arginine, a serine
and a threonine (at positions 56, 121 and 198, respectively; see Fig,
3 A and B and Fig. 4). Hence, it is not surprising that the removal
of this additional interaction with Y161 fails to significantly disturb
the binding of glutamate to the Aplysia receptor. Furthermore
Y161 is binding the same beta sheet of the receptor as does S163
and is thus not providing an interaction with an independent
secondary structure.
The role of the two arginines that are not shared by the
two receptors. As can be seen in Fig. 5, both the R135A
mutation in GluClAc2 (position 93) and the R111L mutation in
GluCla2b (position 37) eliminate the response to 1 mM glutamate
(Figures 5A and 5C, respectively), however both of these
mutations show robust responses at higher glutamate concentra-
tions. Neither of these two arginines, both of which bind the a-
carboxyl group of glutamate, are essential for glutamate binding,
however they are not equivalent. Indeed, in the double mutation
in GluClAc2 (L79R+R135A; Fig. 5B) which moved the arginine
from position 93 to position 37, the response was suppressed at all
concentrations (see Fig. 6A), whereas in the corresponding double
mutation in GluCla2b (R111L+Q167R), which moved the
arginine from position 37 to 93, moderately-sized responses were
already seen in the response to 10 mM glutamate (Fig. 6B).
From these data it can be seen that GluCla2b can accommo-
date the second arginine binding glutamate either at position 37 or
93. Supporting this statement, the Q167R mutation in GluCla2b,
which adds a third arginine to the binding pocket, did not
dramatically change the activity of the mutated receptor (see
Fig. 5C). On the contrary, GluClAc2 cannot accommodate an
arginine at position 37. Indeed, the single mutation L79R, which
adds a third arginine to the binding pocket of GluClAc2 at position
37, essentially suppressed the response of the receptor at all
glutamate concentrations (see Fig. 6A). The difference in the
ability of the two receptors to accommodate the additional
arginine can be explained by comparing the binding sites of the
crystallographic structure of GluClCryst with those presented in the
homology model of GluClAc2, and by more precisely studying the
position of the two arginines and their respective environments.
As can be seen in Fig. 3A and B, the two non-common
arginines are not identically positioned relative to glutamate in the
two receptors. In GluClCryst, the arginine at position 37 is located
in the middle of the binding pocket and on the C subunit (see
Fig. 3A and B), and pulls the a-carboxyl group towards the center
of the binding pocket, whereas the arginine at position 93 in
GluClAc2 (R135) is located at the far end of the binding pocket on
the P subunit of the dimer, with the a-carboxyl group facing in the
corresponding direction (see Fig. 3A and B). These differences
result in a different glutamate bioactive conformation in the two
receptors. The residues aligned with the non-common arginines
are similarly positioned (L79 in GluClAc2 and P93 in GluClCryst,
Fig. 3A and B). The difference in the effectiveness of the double
mutation experiments results from the different environment of the
residue at position 37 in the two receptors: in particular with
respect to the residues at position 54 which are T54 in GluClCryst
and Y96 in GluClAc2 (see Figures 3A and 5B). The mutations of
the two non-common arginines (R135 at position 93 in GluClAc2
and R111 at position 37 in GluCla2b) demonstrate that 1) in
neither of the two receptors is the binding of an arginine to the a-
carboxyl group of glutamate critical, 2) the non-common arginines
define the orientation of the glutamate at the binding site, and 3) in
neither receptor can one of the two non-common arginines
substitute for the other.
The role of Y96 in GluClAc2. On the other hand, the Y96T
mutant, like the Y96A mutant, showed essentially no response
even to 100 mM glutamate, whereas the mutation Y96F did not
affect receptor activation (see Fig. 5A). It can be concluded, thus,
that the Y96 residue owes its major role in the binding pocket to
the hydrophobic contact that its phenyl ring makes with
glutamate. The stability of the link between Y96 and glutamate
depends, however, on the hydrophobic contact that Y96 has with
L79 (position 37). This latter hydrophobic support presumably
orients Y96, making it possible for its phenyl ring to keep
glutamate in an extended conformation (Fig. 3A and B). This
hypothesis is consistent with the observed effect of the L79R
mutation: indeed, an arginine’s side chain is longer than that of a
leucine, therefore this L79R mutation would prevent Y96 from
adopting the conformation that accommodates glutamate in the
binding pocket. Thus, the link between L79 and glutamate is
obtained via Y96 in GluClAc2, whereas in GluCla2b, a direct
interaction between R37 and glutamate is responsible for the
stabilization between the b1 sheet of the receptor and the ligand.
This situation results in different glutamate conformations in
GluClCryst and GluClAc2 characterized by a longer distance (d1)
between amino and c-carboxyl groups in GluClCryst (4.9 A˚) than
in GluClAc2 (4.4 A˚) (see [48] for d1 definition).
Examination of the different pharmacological sensitivities
of the Aplysia and nematode receptors in light of the
model
As was seen in Fig. 1, differences in the responses of the
nematode and Aplysia receptors were observed when they were
exposed to GABA, b-alanine and taurine. These agonists activate
and desensitize GluClAc2, whereas they have no effect on
GluCla2b.
All three of these ligands lack the a-carboxyl group found in
glutamate, and two of the three (b-alanine and taurine) are shorter
than glutamate. The weaker potency of these agonists compared to
glutamate can thus be explained by the loss of the interactions in
which the a-carboxyl group was involved. Yet they still activate the
receptor which is consistent with the mutagenesis data of R135A.
Indeed the potency of GABA and b-alanine on the WT is similar
to that of glutamate on the R135A mutant. Nevertheless, it is
worth noting that even if these ligands lack the a-carboxyl group of
glutamate, there remains a difference in the response of the two
receptors to these ligands. We have already seen that glutamate
adopts different bioactive conformations in the binding pockets of
the two receptors, so the three ligands were docked in GluClAc2’s
homology model to illustrate the structural explanation for these
experimental observations. The results are shown in Fig. 7.
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Figure 7. Similar binding modes for the three additional ligands in GluClAc2. 2D diagram representing the interactions between the
binding pocket residues of the homology model for GluClAc2 and (A) b-alanine, (B) GABA and (C) taurine. Ligands are represented in lines. Only the
polar hydrogens that are involved in interactions with the receptor are explicitly represented. Residues are depicted as circles in which the residue
type, number and position (the latter in parentheses) are written on a colored background which indicates the subunit to which the residue belongs
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A first observation stemming from the dockings is that the c-
carboxyl group of GABA and b-alanine, and the sulfonate moiety
of taurine bind to GluClAc2 with the same network of interactions
as does the c-carboxyl group of glutamate (R98, S163, T238).
However, the lack of an a-carboxyl group in these agonists results
in R135 no longer being involved in any interaction with the
ligands. Nevertheless, as described above, this loss of interaction
does not prevent the receptor activation but simply reduces the
potency of the agonist.
Secondly, one can observe that as the carbon chain of the ligand
is shortened, the a-amino group is closer to Y96 than it is when
glutamate is docked. As can be seen in Fig. 7, the a-amino group
of the three ligands is involved in a cation-p interaction with Y96.
This new interaction, not present when glutamate is docked in
GluClAc2, stabilizes the a-amino group of these ligands, and could
partly compensate the loss of interaction with R135. This thus
supports the experimental observation that GABA, b-alanine and
taurine can weakly activate GluClAc2.
Finally, we can compare the organization of the binding pockets
of GluClAc2 and GluClCryst (and thereby that of GluCla2b) and
notice that, structurally, Y96 in GluClAc2 and R37 in GluClCryst
are close together on their b2 and b1 sheets, respectively, and are
on the same subunit (see Fig. 3A and B). Because of the short d1
distance in b-alanine and taurine, their a-amino group function is
nearer to the arginine at position 37 in the nematode, thus creating
a repulsion between the two positive charges which impedes the
binding of these ligands. Moreover, this repulsion is screened by
the a-carboxyl group in glutamate. The absence of this group in
GABA, b-alanine and taurine suppresses the screening effect and
allows the repulsion between the a-amino group of those ligands
and R37.
Residues at positions 37, 54 and 93 appear to determine
the pharmacology of other pentameric receptors much in
the same way as they do that of GluClAc2. GluClAc2 is not
the only pentameric receptor that fails to be selective for its
defining agonist. The GABAA-r receptor, in addition to being
activated by GABA, is also activated by b-alanine and taurine, and
the glycine receptor, like the GluClAc2 receptor, can also be
activated by all three of the additional agonists [40–43]. Figure 8
provides us with an alignment of the two nematode receptors, the
GluClAc2 receptor and the two vertebrate receptors. It indicates
the residues that appear to be critical for determining the different
pharmacological sensitivities of these five receptors.
As can be seen in the alignment shown in Fig. 8, the two
nematode receptors have an arginine at the position 37 which has
been shown to be a critical binding residue for those receptors.
None of the other four receptors indicated in Fig, 8 has a positively
charged residue at that position. Likewise, at position 54, only the
two nematode receptors have a threonine instead of the tyrosine or
phenylalanine that are seen in the molluscan and vertebrate
receptors (Glya and GABAA-r) (see Fig. 9). That is, all of the
receptors that bind ligands bearing only one acidic group
(GluClAc2, Glya and GABAA-r) have either a phenylalanine or
a tyrosine at position 54, whereas GluCla2b, which is incapable of
binding those supplementary ligands, does not contain a residue
with a benzyl side-chain at position 54. The importance of such
residues has already been demonstrated for the binding of glycine
and GABA to the Glya and GABAA-r receptors, respectively [46–
47].
Residues binding the amino and c–carboxyl groups of
glutamate in GluClCryst and GluAc2 are conserved in the glycine
and GABAA-r receptors and bind the same type of functional
groups in those receptors. These residues are found in green and
yellow boxes in Figure 9 (positions 150, 151, 201, 56, 121, 198).
We have seen that for the ligands that lack an a-carboxyl group,
Y96 in GluClAc2 interacts with the a-amino group. We can
therefore hypothesize that the same residue plays a similar role in
the Glya and GABAA-r receptors (see Fig. 9 and [46–47]).
Finally, one can observe that unlike GluClAc2, neither Glya nor
GABAA-r has a positively charged residue at position 93. Indeed,
GABA does not have an a-carboxyl group and the carboxylate of
glycine serves the role of the c-carboxyl group of glutamate [46]
(Fig. 9), hence no evolutionary pressure was put on this position to
keep a residue that could bind with this moiety. This supports the
hypothesis that no arginine is needed at position 93 to bind b-
alanine, GABA and taurine in GluClAc2. Thus, the similar broad
pharmacology shared by GluClAc2, Glya and GABAA-r can be
explained by the presence of a non-positively charged residue at
position 37 and a residue with a benzyl side-chain at position 54.
Residues at positions 37 (b1-sheet), 54 and 56 (b2-sheet)
are located on secondary structure elements delimiting a
loop coupling the ligand binding and the gating
domains. Calimet et al. [49], through long molecular dynam-
ics, proposed a mechanism for the channel gating of GluClCryst. In
this mechanism, the movement of loop C of the principal face
(defined by residues between cysteines at positions 191 and 203 in
Fig. 2 and indicated in Fig. 8) opens and closes the binding pocket.
That movement is coupled with a global twist of the b sheet
sandwiches of the extracellular domain, triggering the movement
of the b1–b2 loop (between positions 40 and 48 in Fig. 2). This
loop interacts with the loop between helices 2 (M2) and 3 (M3) of
the transmembrane domain named M2–M3 loop (Fig. 8 and 10).
V45 of loop b1–b2 can be either on one side or the other of P268
of M2–M3 loop, the transition being possible when loop C is
opened. Finally, the position of loop M2–M3 influences the tilt of
M2, and therefore the open or closed form of the channel (Fig. 10)
[49].
The conclusions drawn above fit well with the proposed
mechanism: residues at position 37 and 54, found to be essential
and to determine the pharmacology of certain pentameric
receptors, are located on the b1 and b2 sheets, as is the residue
at position 56. The ligand must bind to the receptor before the
closing of loop C which triggers activation of the receptor channel.
In GluClAc2, the basic residue at position 56, along with the
hydrophobic and aromatic residues at positions 37 and 54 (L79,
Y96 and R98) make it possible, firstly, for a ligand with only one
acidic group to interact with R98, and secondly for any positively
charged or neutral atoms to interact with Y96. This explains the
broader pharmacology of GluClAc2 compared to that of
GluClCryst, for which the two basic residues (R37 and R56) only
accept ligands such as glutamate that contains two acidic groups.
Furthermore, one can observe in Fig. 8 that the b1–b2 loop’s
central residues are not conserved throughout all of these
receptors, in particular at position 45 (V45 is the main residue
interacting with the highly conserved proline of the M2–M3 loop
P268 in GluClCryst [49]). Thus, one can hypothesize that the exact
mechanism of interaction and communication between the loops
b1–b2 and M2–M3 is not the same in every receptor. This offers a
possible reason for which the triple ‘‘reverse’’ mutation of
(see Fig. 3 and Fig. 4). Backbone and side chain hydrogen bonds are represented by green and blue arrows, respectively. Salt bridges are represented
by purple arrows, p interactions are represented by orange lines. Atom colors as in Fig. 3B.
doi:10.1371/journal.pone.0108458.g007
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GluCla2b (R111L+Q167R+T128Y) failed to yield responses to
the other three agonists to which the non-mutated GluClAc2
receptor responds.
The fidelity of the two binding pockets to their
respective phylogenetic groupings
Apparent orthologs of the GluClAc2 receptor found in
other molluscs and annelids. Alignments of the N terminal
region of the crystalized receptor with that of the other glutamate-
Figure 8. Alignment of the residues from the binding pocket region through the third transmembrane region of several ligand-
gated ion channels. The alignment contains the sequences from four invertebrate glutamate-gated chloride channels (GluClCryst and GluCla2b
from C. Elegans and GluClAc1 and GluClAc2 from Aplysia californica), and those from two vertebrate receptors: the glycine receptor Glya1 from Rattus
norvegicus (accession #CAC35979 ) and the GABA receptor from Homo sapiens, GABAA-r1 (accession #EAW48558). The second line represents the
secondary structure of GluClCryst: the blue arrows represent b-sheets; the orange tubes, the a-helices. Loop C and helices M1, M2 and M3 are indicated
above the alignment. Positions 37, 54 and 93 are indicated in black boxes. Identical, strongly similar and weakly similar residues are highlighted,
respectively, in dark blue, medium blue and light blue. Residues of interest for the binding of glutamate that were unveiled in this article are
surrounded by violet rectangles when the residues are on the Principal face, and are surrounded by yellow rectangles when on the Complementary
face. Residues surrounded by a red rectangle are involved in the opening/gating mechanism of the ion channel. The importance of a conserved
proline in the M2–M3 extracellular loop will be discussed in Figure 10.
doi:10.1371/journal.pone.0108458.g008
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gated chloride channels from C. elegans, as well as with the
orthologous channels from other nematodes and arthropods,
reveals that the binding mode as identified by crystallization
represents that of both the nematode and the arthropod glutamate
receptors. In contrast, an alignment of the N terminal region of the
Aplysia (GluClAc2) receptor with 2-cys loop receptors from the
nematodes and arthropods revealed no ecdysozoan receptors with
a similar binding mode. On the other hand, a search of three
lophotrochozoan genomes (Lottia gigantea, Capitella teleta, and
Helobdella robusta) revealed two sequences from Capitella, three
Figure 9. Corresponding numbers for aligned residues in GluCl from nematodes and Aplysia, Glua1 and GABAA-r1. List of (1) the
residues identified by the crystallized structure of the binding pocket of the two nematode receptors GluClCryst and GluCla2b, (2) the residues
predicted by the homology model for the binding pocket of GluClAc2 and (3) the corresponding aligned residues of four other receptors (GluCla2b,
Glya1, GABAA-r1 and GluClAc1) all of which were included in the alignment in Figure 8. The aligned residues fall into one of three categories defined
by their known or anticipated site of interaction with the relevant ligand: a-amino group, c-carboxylate/c-sulfonate group, or a-carboxylate group.
The aligned residues on a green background are identical, those on a yellow background are similar, whereas those on a red background are
different. Note that at position 54, where the nematode receptors both have a non-binding threonine, there is a residue shown to be critical for
agonist binding in GluClAc2 (Y96). The other Aplysia receptor as well as the glycine and GABA receptors all show an identical or similar residue to that
of the GluClAc2 receptor at that position.
doi:10.1371/journal.pone.0108458.g009
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sequences from Helobdella and one sequence from Lottia that
appear to be orthologs of GluClAc2 (see Fig. 11A).
It can be seen in Fig. 11A that none of the 2-cys loop sequences
found in any of the three genomes, including the six predicted to
be orthologs to GluClAc2, have a tyrosine aligning with Y161 of
GluClAc2. However, since our mutagenesis experiments showed
that the tyrosine was not necessary for obtaining a normal
glutamate response, we have retained those six sequences as
probable glutamate-gated chloride channels. Our mutagenesis
experiments also showed that the mutation Y96F in no way
affected the response of GluClAc2 to glutamate, so we have
considered that the phenylalanine in that position in one of the
selected sequences (Ct_178435) to be isofunctional with the
tyrosine found in GluClAc2.
An apparent ortholog of the GluClAc1 receptor is found in
the mollusc Lottia gigantean. It is interesting to note that
whereas two orthologs were found in Capitella and three in
Helobdella, only one GluClAc2 ortholog appears to exist in the
Lottia genome. However, a second Lottia sequence was found that
appears to be an ortholog of GluClAc1, the second glutamate-
gated chloride channel cloned from Aplysia that was described by
Kehoe et al. [14]. An alignment of GluClAc1 and its ortholog
from Lottia gigantea is shown in Fig. 11B. It can be seen that
neither the GluClAc1 receptor, nor its Lottia ortholog, has an
arginine aligning with the critical R98 of the GluClAc2 receptor
(see GluClAc1 residue number 95 in Fig. 9).
It was shown in Figures 5 and 6 that, under the 24 hour
transfection constraints used here, a R98S mutation in GluClAc2
eliminated the glutamate response - even to a 100 mM concen-
tration. Likewise, no response to 1 mM glutamate could be
obtained from the expression of GluClAc1, which has a serine in
that position in the WT. In the previous study on the Aplysia
Figure 10. 3D representation of the whole ion channel [49] of GluClCryst (PDB code: 3RIF). Only two adjacent subunits are explicitly
displayed, the three others are represented by the transparent surface. Alpha-helices are represented by tubes, beta-sheets by arrows (b1–b2 sheet in
red, loop C in green, M2 helices and M2–M3 loop in blue). Principal and complementary subunits are colored, respectively, in violet and yellow.
Glutamate is represented as CPK volumes, R37, V45, R56, and P268 are displayed in ball and stick. According to Calimet et al. V45 from b1–b2 loop
and P268 from M2–M3 loop are involved in the gating mechanism. Interestingly the critical residues at positions 37, 54, 56 belong to b1–b2 sheets.
doi:10.1371/journal.pone.0108458.g010
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receptors [14], responses were obtained from GluClAc1 only when
a much longer transfection period was used.
Attempts to dock glutamate in the homology model of
GluClAc1
An attempt to dock glutamate in the homology model of
GluClAc1 (see Materials and Methods) was unsuccessful: when the
docked glutamate was subjected to a molecular dynamics, it did
not reach a stable conformation, thus indicating that the poor
experimental activation of GluClAc1 by glutamate is reflected in
the instability of glutamate in the binding pocket of GluClAc1’s
model. However, a simple change in the two binding residues of
GluClAc1 that were not aligned with the same amino acid in
GluClAc2 permitted the stable docking of glutamate in the
GluClAc1 homology model (see Materials and Methods). Those
residues are found in GluClAc1 at position 56 (residue number 95,
Fig. 9) where the serine in GluClAc1 was changed to an arginine
as is found at the equivalent position in GluClAc2 (residue number
98, Fig. 9) and at position 119 (residue number 158, Fig. 9) where
Figure 11. Orthologs of GluClAc2 (A) and GluClAc1 (B) obtained from three other lophotrochozoan species. A: Sequence alignment of
predicted proteins from Capitella teleta (Ct), Helobdella robusta (Hr), and Lottia gigantea (Lg) with residues of the GluClAc2 receptor from Aplysia
californica (Ac). The binding residues predicted by the homology model of GluClAc2 are bold and surrounded by either violet (P subunit) or yellow (C
subunit) rectangles. Residue numbers from GluClAc2 are indicated above the alignment. B: Alignment of GluClAc1 and the second Lottia gigantea
sequence (Lg_125242) which, like GluClAc1, fails to have an arginine at the position corresponding to the R98 of GluClAc2 (position 95 in GluClAc1).
Furthermore neither Lg_125242 nor GluClAc1 have a tyrosine aligned with the position corresponding to Y161 of GluClAc2 (position 158 in GluClAc1).
doi:10.1371/journal.pone.0108458.g011
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the lysine seen in GluClAc1 was changed to the tyrosine found at
the same position in GluClAc2 (residue number 161, Fig. 9).
Conclusion
In conclusion, the present study has revealed that although
many residues of the glutamate binding sites are shared by the
nematode and Aplysia glutamate-gated chloride channels, a few
residues interacting with the a-carboxyl group of the ligand differ
between the receptors. Two of the residues that differ appear to be
responsible for the different pharmacological profiles of the two
receptors. These residues are located at positions 37 and 54 (see
Fig. 2).
In the Aplysia receptor the residues at these two positions are a
leucine (L79) and a tyrosine (Y96). Y96 plays a significant role in
permitting the docking of all four of the agonists by the
promiscuous hydrophobic contacts its phenyl ring is able to make
with the agonists. In addition, in the ligands lacking the a-carboxyl
group, as the carbon chain of the ligand shortens the a-amino
group becomes closer to Y96, thereby permitting a cation-p
interaction between that residue and the a-amino group.
Furthermore, the leucine at position 37 in the Aplysia receptor
(as opposed to the arginine in the same position in the nematode
receptor) assists in ensuring the binding efficacy of Y96 by its
hydrophobic support of that residue.
In the nematode receptor, for neither the arginine at position 37
nor the threonine at position 54 is there a possibility of a direct
binding of the other ligands, and in fact, the arginine at position 37
may well have a repulsive influence on the ability of those ligands
to bind.
The fact that the GABAA-r and Glya receptors have residues at
positions 37 and 54 with the same characteristics as those found in
GluClAc2, rather than with those of the nematode receptors,
permit us to predict that the residues at those two positions are the
ones responsible both for the failure of the nematode GluClRs to
bind additional amino acids and, conversely, for the ability of
GluClAc2 and GABAA-r and Glya receptors to do so.
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